Abstract
Cardiovascular disease (CVD) continues to be the major cause of death in the developed countries. Moreover, the cardiovascular risk factors leading towards the development of CVD, mainly type 2 diabetes and obesity, are on the rise. The current preventive and therapeutic management, centred on the control of traditional risk factors, is clearly not enough to stop this pandemic. Therefore, the search for new biomarkers in CVD is a priority in most clinical research programs. Currently, interest in gut microbiota has peaked due to its association with cardiovascular and non-cardiovascular diseases. The present review considers the current situation regarding the influence of gut microbiota on CVD and particularly, its influence on the main traditional risk factors that lead to CVD, such as lipids, diabetes, hypertension and obesity.
Keywords: Microbiota, obesity, diabetes, hypertension, lipid metabolism, cardiovascular disease.
Current Pharmaceutical Design
Title:Gut Microbiota: A New Marker of Cardiovascular Disease
Volume: 23 Issue: 22
Author(s): Antonio Garcia-Rios, Jose David Torres-Peña, Francisco Perez-Jimenez and Pablo Perez-Martinez*
Affiliation:
- Reina Sofia University Hospital, Lipids and Atherosclerosis Research Unit. Avda. Menéndez Pidal, s/n. 14004 Córdoba,Spain
Keywords: Microbiota, obesity, diabetes, hypertension, lipid metabolism, cardiovascular disease.
Abstract: Cardiovascular disease (CVD) continues to be the major cause of death in the developed countries. Moreover, the cardiovascular risk factors leading towards the development of CVD, mainly type 2 diabetes and obesity, are on the rise. The current preventive and therapeutic management, centred on the control of traditional risk factors, is clearly not enough to stop this pandemic. Therefore, the search for new biomarkers in CVD is a priority in most clinical research programs. Currently, interest in gut microbiota has peaked due to its association with cardiovascular and non-cardiovascular diseases. The present review considers the current situation regarding the influence of gut microbiota on CVD and particularly, its influence on the main traditional risk factors that lead to CVD, such as lipids, diabetes, hypertension and obesity.
Export Options
About this article
Cite this article as:
Garcia-Rios Antonio , Torres-Peña David Jose , Perez-Jimenez Francisco and Perez-Martinez Pablo *, Gut Microbiota: A New Marker of Cardiovascular Disease, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170317144853
DOI https://dx.doi.org/10.2174/1381612823666170317144853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Healthcare Expenditures Related to BMI and Physical Activity Among Diabetic Older People: Cross-sectional Analysis of Sabe Study
Current Diabetes Reviews Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment
Current Hypertension Reviews Aqueous Extract of Arbutus unedo Inhibits STAT1 Activation in Human Breast Cancer Cell Line MDA-MB-231 and Human Fibroblasts Through SHP2 Activation
Medicinal Chemistry The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design The Potential Clinical Properties of Magnesium
Current Medicinal Chemistry Effects of Perfluorocarbon Dodecafluoropentane (NVX-108) on Cerebral Microvasculature in the Healthy Rat
Current Drug Discovery Technologies ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Seeking the Active Site of the AT1 Receptor for Computational Docking Studies
Drug Design Reviews - Online (Discontinued) Association Between Anemia and Dementia: A Nationwide, Populationbased Cohort Study in Taiwan
Current Alzheimer Research Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Update to Medicinal Chemistry of Nicotinamide in the Treatment of Ischemia and Reperfusion
Medicinal Chemistry Reviews - Online (Discontinued) The Impact of Pregnancy and Parity on Type 1 Diabetes Complications
Current Diabetes Reviews Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery